Linda Liau fanatic, engaged Biotech Investor, GLove spreader, Big Time Cheerleader. I am not an investment advisor or attorney my opinions are just that
@d_stock07734 Someone posted a Norwegian article several weeks back indicating a Norwegian company reached out to $NWBO
Was it realz, who knows but what I do know is that the Kingdom strategy is a profitable one
@alphavestcap Recall poly-icl is owned by a British company
The UK &its citizens benefits are abound by approving #DCVAX &its combination agents shown statistically to improve cure rates &/or to extend lives by enormous leaps forward
Who honestly has a credible argument against my POV
TRY
@alphavestcap If I am not mistaken poly-ICl isn’t on the market. Perhaps this was needed to get access to the adjuvant faster for everyone $NWBO
I doubt this is directly related to #DCVAX itself. It looks like they plan to quickly advance combos for DCVAX though (to me)
@USAnt_IDEA Translation - AI deliberately overwhelmed the digital-analog system that has never done this w/false excessive data streams
Hmm - if I haven’t yet read this is ina SciFi book, it’s now probably too late folks. You enter a less socially valuable genre as it is now scientific fact
$NWBO DCVAX needs to be front and center option for the patients, I did read the story of Laura Nuttall who finally opted for DCVAX after researching but unfortunately not enough of the tumor was saved for the Vaccine Treatment. Doctors should be well informed about DCVAX and at least provide the details and options for the patient and especially ensuring the correct procedures are in place for obtaining the tumor tissue and preserving properly for the Vaccine. https://t.co/qSYuc9YeTb
"Right from the beginning we looked to find other options that might be available. From our own research, we knew that we needed to save the tumour tissue for future immunotherapy purposes. However, tumours can be diffuse and not especially solid on removal and the most important task for the surgeon is the safe removal of the tumour and subsequent pressure in the brain rather than the storage of any removed matter.
We struggled to find the right person to talk to about the stored tumour tissue, nobody seemed to know who we should talk to, and we were bounced around looking for the right person to help us, hitting brick walls on a daily basis. Members of the public are not encouraged to contact the pathology labs but neither the surgeon nor the oncologist seemed to have the information we needed.
We had decided to explore a form of vaccine immunotherapy (DCVax) with a company called Northwest Bio and our oncologist had assured us that he’d been told there was plenty of tissue frozen and available to use for this purpose. However, when their laboratory began the process of producing the lysate to make the vaccine, there was nowhere near enough, just the tiniest sliver. We’d fundraised the money required to produce the vaccine, but the treatment wasn’t possible because we just didn’t have the tumour tissue, this was utterly devastating."
Their is numerous successfull stories of DCVAX for the past decade and most recently @HollensbeAmanda Braelyn.
$NWBO @ALPHAVESTCAP
1)biosectinvestor RE THE MANUFACTURING ISSUE
Re: jesster64 post# 849827
Friday, November 13, 2026 9:24:37 PM
I think there are several substantial facts that undermine the recurring suggestion that manufacturing capacity is holding up DCVax-L approval.
1. NWBO already has an established MHRA-licensed manufacturing facility at Sawston, where DCVax-L has been manufactured for patients under the UK’s Specials program.
2. NHS Blood and Transplant (NHSBT), a UK public-sector organization with extensive experience in collecting and handling human cellular materials, is now supporting the DCVax-L production infrastructure through leukapheresis collection. NWBO reported in October that collections had already begun at Leeds and Oxford. This is an important development involving established UK national healthcare infrastructure.
3. Regulators have already approved individualized cellular immunotherapies presenting substantial manufacturing and logistical challenges. CAR-T therapies, including Kymriah and Yescarta, require collecting patients’ cells, genetically modifying and expanding them, conducting extensive quality testing, and returning the finished products for treatment. These processes are arguably more complex in several respects than DCVax-L manufacturing, and CAR-T therapies can produce severe, potentially life-threatening toxicities that DCVax-L has not demonstrated.
4. NWBO continues to advance Flaskworks automated manufacturing technology, which is intended to improve production efficiency, scalability, and cost. This provides an additional pathway for expanding manufacturing capacity over time.
5. NWBO’s latest quarterly filing confirms that the company continued its active engagement in the MAA review process throughout the third quarter of 2026.
The CAR-T precedent is particularly important. Regulators approved these complex, individualized cellular therapies without requiring their manufacturers to demonstrate the capacity to supply worldwide demand.
The same distinction applies to DCVax-L. Demonstrating an acceptable manufacturing process for regulatory approval is not the same thing as demonstrating sufficient production capacity to meet eventual global demand.
NWBO already has established manufacturing infrastructure, an operational relationship with NHSBT, and an ongoing program to expand and automate production.
These are substantial achievements, not theoretical plans.
The suggestion that DCVax-L cannot receive UK marketing authorisation until NWBO can manufacture enough doses to satisfy worldwide demand has no foundation in the regulatory precedents established by CAR-T therapies or in the requirements for initial UK approval.
And with NWBO reporting continued active engagement in the MAA review process, there is no reason to substitute speculation about manufacturing capacity for what the company has actually disclosed.
2)Followers204Posts25704Boards Moderated0Alias Born04/03/2010📷biosectinvestor
biosectinvestor
Re: FrostyIsland3 post# 849770
Friday, November 13, 2026 7:50:03 PM
Post# of 849907
You have no evidence that the CHM maintained its concerns after oral representations, or even that the hearing has taken place. The August CHM minutes identified outstanding concerns about DCVax-L, but did not disclose what those concerns were, how significant they were, or what happened afterward. They could have involved manufacturing, documentation, or other matters that have since been addressed.
You are taking Braelyn’s appearance in Parliament and the attention from an MP and the Prime Minister and using those events to suggest that NWBO encountered an adverse regulatory development. How exactly do you get from one to the other?
There is also no evidence that NWBO and the NHS are coordinating political pressure on the MHRA. Sharon Hodgson has advocated for patients seeking access to DCVax-L, and Braelyn’s story has attracted political attention. Neither establishes anything about the status of the marketing authorisation application.
The CHM is also an advisory body, not the licensing authority. Its concerns are part of the review process, not an MHRA decision to refuse approval.
What stands out is the attempt to introduce an unsupported negative conclusion while presenting the overall development as encouraging. Calling the parliamentary attention a “good sign” does not make your speculation about the CHM any more credible.
Nothing about these parliamentary events tells us what happened at the CHM after August, what the concerns involved, or whether they have since been resolved. You are asserting knowledge of regulatory developments for which you have provided no evidence.
3)
Home
Boards
US OTC
Biotechs
NorthWest Biotherapeutics Inc (NWBO)
Followers204Posts25704Boards Moderated0Alias Born04/03/2010📷biosectinvestor
biosectinvestor
Re: NWBOfollower post# 849809
Friday, November 13, 2026 7:38:05 PM
Post# of 849908
I appreciate your enthusiasm and the effort you’ve put into researching this, but I have serious doubts about the completeness and reliability of this claimed survey of CHM hearing outcomes. The central problem is that CHM minutes do not always identify the medicines under consideration, making it difficult to establish a complete historical record or reliably match cases to subsequent MHRA decisions. Without a demonstrably comprehensive sample, I don’t see how the conclusions drawn from these seven cases can be justified, particularly the assertion that DCVax-L would “almost certainly” receive approval with conditions.
1. The seven-drug sample has not been shown to be complete.
CHM minutes sometimes discuss medicines without identifying them by name. The August 2026 minutes concerning an unnamed glioblastoma medicine are a perfect example. How many other anonymous cases reached oral hearings since 2020, and how many were subsequently approved? Unless those cases were accounted for, the claimed historical pattern is unreliable.
2. The methodology needs to be demonstrated.
How were the seven medicines identified? Were all CHM hearing-stage cases reviewed, including unnamed medicines? How were their subsequent MHRA decisions verified? Without those answers, there is no basis for treating seven as the complete population.
3. Two approvals cannot establish an “almost certain” outcome.
Even accepting the seven cases, only two reportedly received approval. Two observations cannot establish a dependable regulatory pattern, much less justify a near-certain prediction about DCVax-L.
4. Ordinary licensing requirements are not the same as conditional approval.
Standard marketing authorisations routinely carry safety-monitoring obligations, risk-management requirements and limitations on indicated populations. Unless the poster identifies precisely what conditions were imposed on the two medicines, the comparison risks conflating routine regulatory requirements with substantive conditions imposed because of unresolved efficacy concerns.
5. The CHM does not determine the terms of approval.
The CHM advises; the MHRA makes the regulatory decision. The suggestion that the committee negotiates a compromise between approval and refusal mischaracterizes its role. A CHM hearing does not establish that the eventual MHRA decision must involve conditions.
6. The evidence for DCVax-L has materially strengthened.
The July 2026 BNOS analyses provided additional patient-level comparisons against independent randomized trials, with statistically significant survival advantages. Those findings matter directly to the poster’s concerns about external controls and the reliability of the survival benefit. They should not be discounted when predicting regulatory restrictions.
7. The proposed label restrictions do not follow from the historical evidence.
Nothing in the seven-case analysis establishes that recurrent GBM would be excluded or that approval would be restricted to MGMT-methylated patients. Those are possible outcomes, but the poster provides no demonstrated regulatory precedent or DCVax-L-specific finding that makes them probable.
Bottom line: The argument rests on an unverified denominator, just two reported approvals, and an insufficiently defined concept of “conditions.” That is not a sound foundation for predicting that DCVax-L will “almost certainly” receive a restricted approval. Conditional approval is one possibility, but the evidence presented does not establish that it is the likely outcome, much less a near certainty.
@Teej1k_ Interesting that the poster, who blocked me from replying to him instead of you, asserts 5 years experience suffering longs optimism with an X profile only active for 1 year
$NWBO
They will FUD all the way to and likely past their moment of annihilation
$
I hope more pilots come forward.
It was all a lie. A deliberate shut down to create fear and to squeeze as much money from us as possible before January.
More to come…
I hope more pilots come forward.
It was all a lie. A deliberate shut down to create fear and to squeeze as much money from us as possible before January.
More to come…
@alphavestcap Exactly - maybe their wheels were just greased as well
THE UK IS GETTIN’ REAL DAMN SERIOUS ABOUT BEATIN’ CANCER while thier is a festivus for the rest of us. I got grievances $NWBO
“Make no little plans. They have no magic to stir men’s blood” Dan Burnham, Wizard of Chicago
What is more interesting to consider though is the Million shares that keeping popping up just below prior resistance at $0.1680 lately
I FIND IT ODD that someone w/a million+ shares (0.06% of $NWBO) would shave a large stake at that low a price on the PRECIPICE of UK approval
I see millions of share buys protecting bottom each day now $NWBO
That is a sign someone is likely trying to cheaply acquire. Covering or new $$ it doesn’t matter
Bottom line - no long sells for tax loss this year. We stand mind, skis&legs ready at the top of the ski jump $NWBO
$NWBO, How low does $NWBO go as tax loss selling season approaches? Plus, its clear from August CHM minutes & the UK parliament pleading that there will be at least 6 month clock off from $NWBO. So even Q1 2027 will come & go. Another 50%+ downside? LP’s financiers would know!
#Illini were 8-19 from the free throw line.
Struggled to guard a ball screen
Outrebounded by eight after the first half
Had 16 turnovers
And lost by 6 at No. 16 Texas Tech.
Illinois fought hard and lost, but in my view, no need to panic. In college hoops, losses happen, and there's many months until March.
When Illinois lost to UConn last November, Illini made changes and got better.
#2 Dark Places by Gillian Flynn
Were satanic cults in rural American ever real? Investigate a past set of murders laced with suspicion, hysteria, and rage alongside a team that includes the sister that put him away.
Some may say this is more thriller/mystery. I say applaud subs
Halloween Post Mortem P1
Since the prior season thru this one, I read 13+Horror/adjacent books and will rank them FOR THOSE WHO DARE or care right here. If you like drop a ♥️ and I’ll do it again next year (unlikely 13)
13. The Quiet Tenant - by Clemence Michallon
#3 The Search for Joseph Tully by William Hallahan
This unique novel begins with a dark ages torture that rapidly flips to a modern mystery which feels like you are trapped in the Twilight Zone. I was impressed all around but especially by the atmosphere created &curious ending
News posts the social media comment about raising cash and $IBRX tanks. I don’t love the cash position myself but I’m not concerned of the REV miss. Treatment precedes approval in oncology
The sun starts shining soon but it looks like I need to look elsewhere to reap tax gains
$NWBO, How low does $NWBO go as tax loss selling season approaches? Plus, its clear from August CHM minutes & the UK parliament pleading that there will be at least 6 month clock off from $NWBO. So even Q1 2027 will come & go. Another 50%+ downside? LP’s financiers would know!
Re: j e d post# 849212
Sunday, November 08, 2026 8:54:39 PM
$nwbo @alphavestcap
1)Regarding the finalization of the RWD ECA guidance, remember that MHRA’s 2026 Business Plan says “By the end of Q4, we
will publish guidance on the use of real-world data external control arm,” so announcing it at this summit would make sense.
Whether or not this was holding back an MA decision, who knows.
https://t.co/fxGXmUhV0h
2)Home
Boards
US OTC
Biotechs
NorthWest Biotherapeutics Inc (NWBO)
Followers103Posts7312Boards Moderated0Alias Born06/07/2016📷pgsd
pgsd
Re: None
Monday, November 09, 2026 4:49:00 AM
Post# of 849233
MHRA champions patient voices through new policy
The MHRA plans to consider a diverse range of patient and public opinions when making regulatory decisions.
November 6, 2026
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has unveiled a policy to enhance the role of patients and the public in forming drug and medical device regulation.
Dubbed the Patient and Public Involvement and Engagement (PPIE) Plan 2026-2030, the agency designed the policy to facilitate earlier and wider engagement with both communities and patient groups – allowing it to better consider unique patient needs while shaping its regulatory strategy.
Through this policy, the MHRA plans to inform its decisions through the lived experience of patients. This means that the regulator will consider their opinions when drafting new policies, conducting safety reviews and assessing the risk-benefit profile of a drug or device, as well as how it should govern emerging technologies like artificial intelligence (AI).
This plan builds on the MHRA’s recently announced Strategy 2030, in which the agency aims to streamline drug and device regulation, while working on making the process more patient-centric.
Through PPIE, the MHRA also hopes to hear from a more diverse group of patients by expanding its Patient and Public Community, which will guide the agency in making information about medicines more accessible for all. The MHRA first established this patient group in 2024 to unite patients, charities and patient organisations in a bid to guide MHRA decision-making.
On top of this, the regulator will also work on improving its systems, which it hopes to achieve by strengthening feedback and reporting for greater patient transparency on how their contributions influence decision-making. This will also see the MHRA focus on improving its work with the UK’s health watchdog, the National Institute for Health and Care Excellence (NICE), by diminishing duplication within its patient involvement evidence database.
Thus far, patient involvement has already benefited the MHRA, the agency says, as an advisory group of 23 patient representatives has helped to inform draft guidance and identify key priorities within the context of rare disease.
According to the MHRA’s chair, Anthony Harnden, this plan represents “a vital evolution” in the agency’s approach to patient engagement, as the healthcare landscape enters a period of rapid change.
“Patients and the public can tell us how treatments affect their everyday lives, what benefits they value most and where information needs to be clearer,” Harnden said, adding that the insights will allow the regulator to ask the right questions and make better informed regulatory decisions.
MHRA targets widespread reform
The MHRA debuts PPIE as it looks to enact wider reforms to its regulatory approach, with the agency also looking to release a Women’s Health Plan later this year.
To keep up with the changing landscape, the MHRA is also figuring out the best ways to regulate AI – both when reviewing drug and device applications, and when incorporating it into its own workflow.
This shift can also be seen within wider government initiatives. Recently, British ministers backed all 44 recommendations around AI-enabled medical devices made by its National Commission into the Regulation of AI in Healthcare.
The UK government reforms its approach as global life sciences and healthcare competition mounts – with key established players like the US and up-and-coming leaders like China increasingly attracting attention on the global stage.
Email newsletter icon
https://t.co/RXQtjyAfCT
Wait wait wait again please… I didn’t get to the best part $NWBO
I mean the part that you learn about when you get close to those on top
Taxes, risk diversity, buying power maintenance, its corporate influence=Private Equity groups
THEY CAN BUY OTC & DERIVATIVES
Chew on that